Gut Microbiome Patterns Linked to Specific Cancer Types and Early-Onset Cancers

What's new

A recent study from Mayo Clinic researchers has uncovered specific patterns within the gut microbiome that are associated with various cancer types, including distinct signatures for early-onset cancers. Analyzing stool samples from over 1,300 cancer patients, the team identified 341 bacterial species linked to five different cancer groups. Notably, unique microbial compositions were observed in younger adults (under 50) diagnosed with colorectal and breast cancers compared to older patients. Furthermore, the research highlighted connections between certain gut bacteria and patient survival rates, and even a potential microbial indicator for chemotherapy-induced diarrhea [1].

The science behind it

The study, published in Cell, utilized data from the Mayo Clinic Cancer Microbiome cohort, which collected stool samples from cancer patients across various stages and treatments. These samples were linked to comprehensive clinical data, allowing researchers to explore the intricate relationship between the gut microbiome and cancer. Initial comparisons between cancer patients and a control group of individuals without cancer revealed broad microbial differences. Subsequent, more granular analysis across different cancer types unveiled specific microbial signals. For instance, neuroendocrine tumors were characterized by a reduction in common, health-associated gut bacteria, while liver and intrahepatic bile duct cancers showed elevated levels of bacteria like Enterococcus faecalis. Esophageal cancer, conversely, was linked to higher levels of several Streptococcus species [1].

Particular attention was paid to early-onset cancers, given the rising incidence rates in younger adults. In younger patients with colorectal cancer, researchers observed higher lactate levels and an increased presence of Veillonella parvula, a bacterium known to consume lactate. Early-onset breast cancer presented changes across 64 bacterial species, including lower levels of primary bile acids and a differing abundance of Clostridium scindens, a bacterium involved in bile acid and steroid metabolism. These findings suggest potential biological connections, though they do not establish causation [1].

The study also investigated the microbiome's role in treatment outcomes. Researchers identified specific gut bacteria associated with survival in several cancers, such as Bifidobacterium longum with longer survival in liver and intrahepatic bile duct cancer, and Blautia A massiliensis with shorter survival. Additionally, a significant finding related to chemotherapy side effects emerged: patients receiving 5-fluorouracil (5-FU) who later experienced diarrhea had lower levels of bacterial genes capable of breaking down the drug, primarily attributed to Anaerostipes hadrus. This suggests the gut microbiome might influence how patients tolerate specific treatments [1].

What it means in practice

These findings represent a significant step towards understanding the complex interplay between the gut microbiome and cancer development, progression, and treatment response. Identifying distinct microbial patterns associated with specific cancer types and age groups could pave the way for novel diagnostic tools or personalized therapeutic strategies. For example, understanding the microbial signatures of early-onset cancers might lead to earlier detection methods or targeted interventions for younger patients [1].

The link between the gut microbiome and chemotherapy side effects is particularly promising. If specific microbial profiles can predict a patient's likelihood of developing severe diarrhea from certain chemotherapy drugs, clinicians might be able to proactively manage these side effects, potentially improving treatment adherence and patient quality of life. This could involve dietary modifications, probiotics, or other microbiome-modulating interventions before or during treatment [1].

Ultimately, this research contributes to the growing body of evidence suggesting that the gut microbiome is not just a passive bystander but an active participant in human health and disease. Future research will focus on validating these associations in larger cohorts and investigating whether these microbial changes play a causal role in cancer, which could lead to entirely new avenues for prevention and treatment [1].

Caveats

While this study provides compelling associations, it is crucial to note that it primarily identifies correlations, not causation. The presence of certain bacteria or microbial patterns alongside cancer does not definitively prove that these microbes cause the disease or its progression. Further experimental research is needed to determine the causal mechanisms [1].

The study's findings regarding early-onset cancers, while intriguing, also require further investigation. The observed microbial differences in younger patients with colorectal and breast cancers highlight areas for future study but do not yet offer definitive explanations for the rising incidence rates in these populations. The absence of similar age-related differences in brain cancer, for instance, underscores the specificity and complexity of these microbial associations [1].

Finally, the findings related to chemotherapy toxicity, while promising, are preliminary. The association between Anaerostipes hadrus levels and 5-FU-induced diarrhea was specific to that drug and needs to be validated in larger, independent patient groups before it can be translated into clinical practice. The microbiome is a highly dynamic and individualized ecosystem, and broad generalizations should be approached with caution [1].

Source: [1] https://newsnetwork.mayoclinic.org/discussion/distinct-gut-microbiome-patterns-found-in-5-cancer-groups-and-in-early-onset-cancers/